Activation of the JAK-STAT pathway is necessary for desensitization of 5-HT2A receptor-stimulated phospholipase C signalling by olanzapine, clozapine and MDL 100907

International Journal of Neuropsychopharmacology

Volumn 12, Issue 5, 2009, Pages 651-665

  Singh, Rakesh K ^a   Dai, Ying ^b   Staudinger, Jeff L ^a   Muma, Nancy A ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

5 HT2A receptor; Clozapine; Desensitization; JAK STAT; Olanzapine

Indexed keywords

CLOZAPINE; JANUS KINASE; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OLANZAPINE; PHOSPHOLIPASE C; RGS PROTEIN; RGS PROTEIN 7; SEROTONIN 2A RECEPTOR; STAT PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VOLINANSERIN;

ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DATA ANALYSIS; DESENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; INTERNALIZATION; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION; RNA ISOLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BENZODIAZEPINES; CELL LINE; CLOZAPINE; ENZYME ACTIVATION; FLUOROBENZENES; JANUS KINASES; MAP KINASE SIGNALING SYSTEM; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; STAT3 TRANSCRIPTION FACTOR; TYPE C PHOSPHOLIPASES;

EID: 69749104742     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009590     Document Type: Article

References (62)

1. Aaronson DS, HorvathCM (2002). A road map for those who don't know JAK-STAT. Science 296, 1653-1655.
2. Banes AK, Shaw SM, Tawfik A, Patel BP, Ogbi S, Fulton D, Marrero MB (2005). Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. American Journal of Physiology - Cell Physiology 288, C805-C812.
3. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P (2006). Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. American Journal of Psychiatry 163, 1580-1587.
4. Bowden NA, Scott RJ, Tooney PA (2007). Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophrenia Research 89, 165-168.
5. Burchett SA (2003). In through the out door: nuclear localization of the regulators of G protein signaling. Journal of Neurochemistry 87, 551-559.
6. Burnet PW, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsycho-pharmacology 15, 442-455.
7. Chen CK, Eversole-Cire P, Zhang H, Mancino V, Chen YJ, He W, Wensel TG, Simon MI (2003). Instability of GGL domain-containing RGS proteins in mice lacking the G protein beta-subunit Gbeta5. Proceedings of the National Academy of Sciences USA 100, 6604-6609.
8. Dai Y, Dudek NL, Patel TB, Muma NA (2008). Transglutaminase-catalyzed transamidation: a novel mechanism for Rac1 activation by 5-hydroxytryptamine2A receptor stimulation. Journal of Pharmacology and Experimental Therapeutics 326, 153-162.
9. Damjanoska KJ, Muma NA, Zhang Y, D'Souza DN, Garcia F, Carrasco GA, Kindel GH, Haskins KA, Shankaran M, Petersen BR, Van de Kar LD (2003). Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol-l-yl)-1- methylethylamine fumarate (Ro 60-0175) is not a selective 5- hydroxytryptamine(2C) receptor agonist. Journal of Pharmacology and Experimental Therapeutics 304, 1209-1216.
10. Decker T, Kovarik P, Meinke A (1997). GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. Journal of Interferon & Cytokine Research 17, 121-134.
11. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991). Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 4, 121-156.
12. DiBello PR, Garrison TR, Apanovitch DM, Hoffman G, Shuey DJ, Mason K, Cockett MI, Dohlman HG (1998). Selective uncoupling of RGS action by a single point mutation in the G protein alpha-subunit. Journal of Biological Chemistry 273, 5780-5784.
13. Doat-Meyerhoefer MM, Hard R, Winter JC, Rabin RA (2005). Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas. Pharmacology Biochemistry and Behavior 81, 750-757.
14. Dohlman HG, Thorner J (1997). RGS proteins and signaling by heterotrimeric G proteins. Journal of Biological Chemistry 272, 3871-3874.
15. Egan C, Grinde E, DuPre A, Roth BL, Hake M, Teitler M, Herrick-Davis K (2000). Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 35, 144-150.
16. Egan CT, Herrick-Davis K, Teitler M (1998). Creation of a constitutively activated state of the 5-hydroxy-tryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 286, 85-90.
17. Ehret GB, Reichenbach P, SchindlerU,Horvath CM, Fritz S, Nabholz M, Bucher P (2001). DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. Journal of Biological Chemistry 276, 6675-6688.
18. Erdely HA, Tamminga CA, Roberts RC, Vogel MW (2006). Regional alterations in RGS4 protein in schizophrenia. Synapse 59, 472-479.
19. Fumagalli F, Frasca A, Sparta M, Drago F, Racagni G, Riva MA (2006). Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Molecular Pharmacology 69, 1366-1372.
20. Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S, Rahman Z, Young KH (2004). Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signalling 16, 711-721.
21. Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Research Bulletin 56, 441-451.
22. Gu Z, Jiang Q, Yan Z (2007). RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Molecular Pharmacology 71, 1030-1039.
23. Guillet-Deniau I, Burnol AF, Girard J (1997). Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway. Journal of Biological Chemistry 272, 14825-14829.
24. Hanley NR, Hensler JG (2002). Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. Journal of Pharmacology and Experimental Therapeutics 300, 468-477.
25. Herrick-Davis K, Grinde E, Gauthier C, Teitler M (1998). Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor. Annals of the New York Academy of Sciences 861, 140-145.
26. Hollinger S, Hepler JR (2002). Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacological Review 54, 527-559.
27. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE (2005). New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 4, 1131-1133.
28. Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS (2004). The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Letters 560, 115-119.
29. Kenakin T (2007). Functional selectivity through protean and biased agonism: who steers the ship? Molecular Pharmacology 72, 1393-1401.
30. Khawaja XZ, Liang JJ, Saugstad JA, Jones PG, Harnish S, Conn PJ, Cockett MI (1999). Immunohistochemical distribution of RGS7 protein and cellular selectivity in colocalizing with Galphaq proteins in the adult rat brain. Journal of Neurochemistry 72, 174-184.
31. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002). Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24.
32. Koelle MR, Horvitz HR (1996). EGL-10 regulates G protein signaling in the C. elegans nervous system and shares a conserved domain with many mammalian proteins. Cell 84, 115-125.
33. Krumins AM, Barker SA, Huang C, Sunahara RK, Yu K, Wilkie TM, Gold SJ, Mumby SM (2004). Differentially regulated expression of endogenous RGS4 and RGS7. Journal of Biological Chemistry 279, 2593-2599.
34. Kuoppamaki M, Palvimaki EP, Hietala J, Syvalahti E (1995). Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13, 139-150.
35. Larminie C, Murdock P, Walhin JP, Duckworth M, Blumer KJ, Scheideler MA, Garnier M (2004). Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. Brain Research. Molecular Brain Research 122, 24-34.
36. Leeman RJ, Lui VW, Grandis JR (2006). STAT3 as a therapeutic target in head and neck cancer. Expert Opinion on Biological Therapy 6, 231-241.
37. Lu XH, Bradley RJ, Dwyer DS (2004). Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Research 1011, 58-68.
38. Meltzer HY (1995). Role of serotonin in the action of atypical antipsychotic drugs. Clinical Neuroscience 3, 64-75.
39. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, 106S-115S.
40. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics 251, 238-246.
41. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001). Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Molecular Psychiatry 6, 293-301.
42. Muma NA, Singh RK, Vercillo MS, D'Souza DN, Zemaitaitis B, Garcia F, Damjanoska KJ, Zhang Y, Battaglia G, Van de Kar LD (2007). Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex. Neuropharmacology 53, 552-562.
43. Olijslagers JE, Perlstein B, Werkman TR, McCreary AC, Siarey R, Kruse CG, Wadman WJ (2005). The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro. European Journal of Pharmacology 520, 77-85.
44. Peroutka SJ, Synder SH (1980). Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry 137, 1518-1522.
45. Rauser L, Savage JE, Meltzer HY, Roth BL (2001). Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. Journal of Pharmacology and Experimental Therapeutics 299, 83-89.
46. Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, Ahn YM, Kang UG, Juhnn YS, Kim YS (2007). Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Experimental and Molecular Medicine 39, 353-360.
47. Ross EM, Wilkie TM (2000). GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annual Review of Biochemistry 69, 795-827.
48. Roth BL, Ciaranello RD, Meltzer HY (1992). Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. Journal of Pharmacology and Experimental Therapeutics 260, 1361-1365.
49. Roth BL, Palvimaki EP, Berry S, Khan N, Sachs N, Uluer A, Choudhary MS (1995). 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. Journal of Pharmacology and Experimental Therapeutics 275, 1638-1646.
50. Schindler CW (2002). Series introduction. JAK-STAT signaling in human disease. Journal of Clinical Investigation 109, 1133-1137.
51. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe III JA (1995). Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology and Experimental Therapeutics 275, 101-113.
52. Shi J, Zemaitaitis B, Muma NA (2007). Phosphorylation of Galpha11 protein contributes to agonist-induced desensitization of 5-HT2A receptor signaling. Molecular Pharmacology 71, 303-313.
53. Singh RK, Shi J, Zemaitaitis BW, Muma NA (2007). Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. Journal of Pharmacology and Experimental Therapeutics 322, 133-140.
54. Tucker RP (2004). Antisense knockdown of the beta1 integrin subunit in the chicken embryo results in abnormal neural crest cell development. International Journal of Biochemistry & Cell Biology 36, 1135-1139.
55. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614.
56. Willins DL, Alsayegh L, Berry SA, Backstrom JR, Sanders-Bush E, Friedman L, Khan N, Roth BL (1998). Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo. Annals of the New York Academy of Sciences 861, 121-127.
57. Willins DL, Berry SA, Alsayegh L, Backstrom JR,Sanders-Bush E, Friedman L, Roth BL (1999). Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience 91, 599-606.
58. Wolf WA, Schutz LJ (1997). The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. Journal of Neurochemistry 69, 1449-1458.
59. Wolff MC, Leander JD (2000). A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon. Behavioural Pharmacology 11, 355-364.
60. Wrighting DM, Andrews NC (2006). Interleukin-6 induces hepcidin expression through STAT3. Blood 108, 3204-3209.
61. Zeng XP, Le F, Richelson E (1997). Muscarinic m4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology 321, 349-354.
62. Zhang JH, Simonds WF (2000). Copurification of brain G-protein beta5 with RGS6 and RGS7. Journal of Neuroscience 20, RC59.